• 1
    Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J. Clin. Oncol. 1999; 17: 1499507.
  • 2
    Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 2005; 23: 700512.
  • 3
    Karakiewicz PI, Shariat SF, Palapattu GS et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J. Urol. 2006; 176: 135461.discussion 61–2.
  • 4
    Shariat SF, Karakiewicz PI, Palapattu GS et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin. Cancer Res. 2006; 12: 666376.
  • 5
    Kattan M. Statistical prediction models, artificial neural networks, and the sophism ‘I am a patient, not a statistic. J. Clin. Oncol. 2002; 20: 8857.
  • 6
    Porter CR, Kodama K, Gibbons RP et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J. Urol. 2006; 176: 56974.
  • 7
    Skuladottir H, Olsen JH. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J. Clin. Oncol. 2003; 21: 303540.
  • 8
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987; 40: 37383.
  • 9
    Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974; 111: 5864.
  • 10
    Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J. Urol. 2004; 172: 9104.
  • 11
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496509.
  • 12
    Harrell FE Jr, Mark KL, Lee DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996; 15: 36187.
  • 13
    Dotan ZA, Bianco FJ Jr, Rabbani F et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J. Clin. Oncol. 2005; 23: 19628.
  • 14
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917.
  • 15
    Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin. Cancer Res. 2005; 11: 866973.
  • 16
    Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 5728.
  • 17
    Chun FK, Graefen M, Briganti A et al. Initial Biopsy Outcome Prediction-Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. Eur. Urol. 2007; 51: 123643.
  • 18
    Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J. Clin. Epidemiol. 2001; 54: 77481.
  • 19
    Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J. Clin. Epidemiol. 2003; 56: 4417.
  • 20
    Briganti A, Chun FK, Salonia A et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur. Urol. 2007; 51: 1129.discussion 9–20.
  • 21
    Briganti A, Karakiewicz PI, Chun FK et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur. Urol. 2007; 51: 157381.
  • 22
    Karakiewicz PI. Editorial comment on: Laparoscopic extended pelvic lymph node dissection for prostate cancer: description of the surgical technique and initial results. Eur. Urol. 2007; 52: 13556.
  • 23
    Keller H, Lehmann J, Beier J. Radical perineal prostatectomy and simultaneous extended pelvic lymph node dissection via the same incision. Eur. Urol. 2007; 52: 3848.
  • 24
    Turkeri L. The extent of lymph node dissection in patients with localised prostate cancer: debate continues. Eur. Urol. 2007; 51: 14724.
  • 25
    Albertsen PC, Hanley JA, Barrows GH et al. Prostate cancer and the Will Rogers phenomenon. J. Natl. Cancer Inst. 2005; 97: 124853.
  • 26
    Porter CR, Gallina A, Kodama K et al. Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy. Eur. Urol. 2007; 52: 44654.